Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents in Hemodialysis Centers in Croatia

Roche

Status: Completed

Conditions: Renal Anemia of Chronic Kidney Disease

Treatments: Other: No intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT02625844

ML25720

Details and patient eligibility

About

This study is to document the time spent by health care personnel on anemia-related tasks, including preparation, distribution and administration of monopegylated epoetin beta (Mircera) or other erythropoiesis-stimulating agents (ESAs) in patients with end stage renal disease in hemodialysis centers in Croatia. The total average time will be determined for the same number of patients on monopegylated epoetin beta and patients on other ESAs. In addition, qualitative information will be obtained on changes in practice patterns that may have occurred with the introduction of monopegylated epoetin beta.

Enrollment: 110 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adult patients

Exclusion criteria

• Hypersensitivity to the active substance or to any of the excipients
• Uncontrolled hypertension

Trial design

110 participants in 2 patient groups

Monopegylated Epoetin Beta

Description:

Health care personnel performing anemia management tasks for patients using monopegylated epoetin beta.

Treatment:

Other: No intervention

Other Erythropoiesis Stimulating Agents (ESAs)

Description:

Health care personnel performing anemia management tasks for patients using other ESAs.

Treatment:

Other: No intervention